Interleukin-1: Biological Effects in Human Hematopoiesis

References

• Gabrilove J., Jakubowski A., Scher H., et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N. Engl. J. Med. 1988; 318: 1414–1419
   PubMed Web of Science ®Google Scholar
• Antman K. S., Griffin J. D., Elias A., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N. Engl. J. Med. 1988; 319: 593–598
   PubMed Web of Science ®Google Scholar
• Brandt S., Peters W., Atwater S., et al. Effect of recombinant human granulocyte-macrophage colony-stimulaling factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 1988; 318: 869–876
   PubMed Web of Science ®Google Scholar
• Gulati S. C., Bennett C. L. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann. Intern. Med. 1992; 116: 177–182
   PubMed Web of Science ®Google Scholar
• Advani R., Chao N., Horning S., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann. Intern. Med. 1992; 116: 183–189
   PubMed Web of Science ®Google Scholar
• Scher H., Seidman A., Bajorin D., et al. Escalated methotrexate, vinblastine, Adriamysin and cisplatin (E-MVAC) with granulocyte colony-stimulating factor in urothelial cancer. Proc. Am. Soc. Clin. Oncol. 1992; 11: 199, (abst).
   Google Scholar
• Gabrilove J. L. Hematopoietic growth factors. Cancer Medicine, 3rd edition, J. F. Holland. Cancer Medicine, NY, (in press):.
   Google Scholar
• Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–1652
   PubMed Web of Science ®Google Scholar
• Obal F., Opp M., Cady A. B., et al. Interleukin-l α and an interleukin-lb˜ fragment are somonogenic. Am. J. Physiol. 1990; 259: R439–446
   PubMed Web of Science ®Google Scholar
• Ferreira S. H., Lorenzetti B. B., Bristow A. F., Poole S. Interleukin-1b˜ as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988; 334: 698–700
   PubMed Web of Science ®Google Scholar
• Beasley D., Cohen R. A., Levinsky N. G. Interleukin-1 inhibits contraction of vascular smooth muscle. J. Clin. Invest. 1989; 83: 331–335
   PubMed Web of Science ®Google Scholar
• Fibbe W. E., van Damme J., Billiau A., et al. Interleukin-1 induces human marrow stromal cells in long-term culture to produce granulocyte colony-stimulating factor and macrophage colony-stimulating factor. Blood 1988; 71: 430–435
   PubMed Web of Science ®Google Scholar
• Gasparetto C., Laver J., Abboud M., et al. Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model. Blood 1989; 74: 547–550
   PubMed Web of Science ®Google Scholar
• Tosato G., Jones K. D. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood 1990; 75: 1305–1310
   PubMed Web of Science ®Google Scholar
• Bot F., Schipper P., Broeders L., Delwel R., Kaushansky K., Lowenberg B. Interleukin-l α also induces granulocyte-macrophage colony-stimulating factor in immature normal bone marrow cells. Blood 1990; 76: 307–311
   PubMed Web of Science ®Google Scholar
• Iscove N. N., Shaw A. R., Keller G., et al. Net increase in pluripotential hematopoietic percursors in suspension culture in response to IL-1 and IL-3. J. Immunol. 1989; 142: 2332–2337
   PubMed Web of Science ®Google Scholar
• Johnson C. S., Keckler D. J., Topper M. I., Braunschweiger P. G., Furmanski P. In vivo hematopoietic effects of recombinant interleukin-lα in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoieis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678–683
   PubMed Web of Science ®Google Scholar
• Neta R., Monroy R., MacVittie T. J. Utility of interleukin-1 in therapy of radiation injury as studied in small and large animal models. Biotherapy 1989; 1: 301–311
   PubMedGoogle Scholar
• Gasparetto C., Smith C., Gillio A. Enrichment of peripheral blood stem cells with cytokine treatment in a preclinical primate model. Blood 1990; 541a, (suppl. 1): (abst.).
   Google Scholar
• Moreb J., Zucali J. R. Role of interleukin-1 in 4-hydroperoxycyclophosphamide toxicity to bone marrow progenitor cells: a review. Biotherapy 1989; 1: 273–280
   PubMedGoogle Scholar
• Neta R., Monroy R., MacVittie T. J. Utility of interleukin-1 in therapy of radiation injury as studied in small and large animal models. Biotherapy 1989; 1: 301–311
   PubMedGoogle Scholar
• Stork L., Barczuk L., Kissinger M., Robinson W. Interleukin-1 aceelerates murine granulocyte recovery following treatment with cyclophosphamide. Blood 1989; 73: 938–944
   PubMed Web of Science ®Google Scholar
• Laver J., Abboud M., Gasparetto C., et al. Effects of interleukin-1 on hematopoietic progenitors after myelosup-pressive chemotherapy. Biotherapy 1989; 1: 293–300
   PubMedGoogle Scholar
• Moore M. A. S., Warren D. J. Synergy of interleukin-1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc. Natl. Acad. Sci. USA 1987; 84: 7134–7138, 1987
   PubMed Web of Science ®Google Scholar
• Moore M. A. S., Stolfi R. L., Martin D. S. Hematologic effects of interleukin-1b˜, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor in tumor-bearing mice treated with fluorouracil. J. Natl. Cancer Inst. 1990; 82: 1031–1037
   PubMed Web of Science ®Google Scholar
• Lovett D., Kozan B., Hadam M., Resch K., Gemsa D. Macrophage cytotoxicity: Interleukin-1 as a mediator of tumor cytostasis. J. Immunol. 1986; 136: 340–347
   PubMed Web of Science ®Google Scholar
• Gaffney E. V., Tsai S. C. Lymphocyte-activating and growth-inhibitory activities for several sources of native and recombinant interleukin-1. Cancer Res 1986; 46: 3834–3837
   PubMed Web of Science ®Google Scholar
• Tsai S., Gaffney E. V. Modulation of cell proliferation by human recombinant interleukin-1 and immune interferon. J. Natl. Cancer. Inst. 1987; 79: 77–81
   PubMed Web of Science ®Google Scholar
• North R. J., Neubauer R. H., Huang J. J., Newton R. C., Loveless S. E. Interleukin-2-induced, T cell-mediated regression of immunogenic murine tumors. J. Exp. Med. 1988; 168: 2031–2043
   PubMed Web of Science ®Google Scholar
• Crump W. L., Owen-Schaub L. B., Grimm E. A. Synergy of recombinant human interleukin-1 with interleukin-2 in the generation of lymphokine activated killer cells. Cancer Res. 1989; 49: 149–153
   PubMed Web of Science ®Google Scholar
• McCune C. Interleukin-1 as an adjuvant for tumor vaccines increases survival in mice. Biotherapy 1989; 1: 355–359
   PubMedGoogle Scholar
• Orr F. W., Buchanan M. R., Tron V. A., Guy D., Lauri D., Sauder D. N. Chemotactic activity of endothelial cell derived interleukin-1 for human tumor cells. Cancer Res. 1988; 48: 6758–6763
   PubMed Web of Science ®Google Scholar
• Dejana E., Bertocchi F., Bortolami M. C., et al. Interleukin-1 promotes tumor cell adhesion to cultured endothelial cells. J. Clin Invest 1988; 82: 1466–1470
   PubMed Web of Science ®Google Scholar
• Bani M. R., Garofalo A., Scanziani E., Giavazzi. Effect of interleukin-lb˜ on metastasis formation in different tumor systems. JNCI 1991; 83: 119–123
   PubMed Web of Science ®Google Scholar
• Crown J., Jakubowski A., Kemeny N., et al. A phase I trial of recombinant human interleukin-lb˜ alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 1990; 78: 1420–1427
   Web of Science ®Google Scholar
• Tewari A., Buhles W. C., Starnes H. F. Preliminary report: effects of interleukin-1 on platelet counts. Lancer 1990; 336: 712–714
   PubMed Web of Science ®Google Scholar
• Smith J. W., Urba W. J., Curti B. D., et al. The toxic and hematologic effects of interleukin-l α administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 1992; 10: 1141–1152
   PubMed Web of Science ®Google Scholar
• Kitamura T., Takaku F. A preclinical trial and phase I clinical trial of IL-1. Exp. Med. 1989; 7: 170–177
   Google Scholar
• Steis R., Smith J., Janik J., et al. Phase I study of recombinant human interleukin-1b˜. Proc. Am. Soc. Clin. Oncol. 1991; 10: 210, (abst).
   Google Scholar
• Dennis D., Chachoua A., Caron D., et al. Biologic activity of interleukin-l α in patients with refractory malignancies. Proc. Am. Soc. Clin. Oncol. 1992; 11: 255, (abst).
   Google Scholar
• Vredenburgh J., Ross M., Kurtzberg J., et al. Phase I trial of interleukin-1b˜ following high-dose chemotherapy and autologous bone marrow transplantation. Blood 1991; 78(suppl. 1)6a, (abst).
   Google Scholar
• Smith J., Urba W., Steis R., et al. Interleukin-la: Results of a phase I toxicity and immunomodulatory trial. Proc. Am. Soc. Clin. Oncol. 1990; 9: 186, (abst).
   Google Scholar
• Starnes H. F. Biological effects and possible clinical applications or interleukin-1. Semin. Hematol. 1991; 28: 34–41
   PubMed Web of Science ®Google Scholar
• Smith J., Longo D., Avord W., et al. Thrombopoietic effects of I1-la in combination with high-dose carboplatin. Proc. Am. Soc. Clin. Oncol. 1992; 11: 252, (abst).
   Google Scholar
• Vadhan-Raj S., Kudelka A., Garrison L., et al. Interleukin-lα increases circulating platelet counts and reduces carboplatin-induced thrombocytopenia. Proc. Am. Soc. Clin. Oncol. 1992; 11: 224, (abst).
   Google Scholar
• Wilson W. H., Bryant G., Jain V., et al. Phase I study of infusional interleukin-1α with ifosfamide, CBDCA and etoposide and autologous bone marrow transplantation. Proc. Am. Soc. Clin. Oncol. 1992; 11: 335, (abst).
   Google Scholar
• Nemunitis J., Buckner C. D., Press O., Lilleby K., Buhles B., Singer J. Phase I trial with interleukin-lb˜ in patients undergoing autologous bone marrow transplantation for acute myelogenous leukemia. Blood 1991; 78%(suppl. 1)8a, (abst).
   Google Scholar
• Buescher E. S., McIlheran S. M., Banks S. M., Kudelka A. P., Kavanagh J. J., Vahdan-Raj S. Normalization of blood granulocyte chemotactic responses in patients undergoing interleukin-1 alpha therapy. Blood 1991; 78%(suppl. 1)3a, (abst).
   Google Scholar
• Starnes H. F., Hartman G., Torti F., Carlson R. W., Tewari A., Buhles W. C. Recombinant human interleukin-1b˜ has anti-tumor activity and acceptable toxicity in metastatic malignant melanoma. Proc. Am. Soc. Clin. Oncol. 1991; 10: 292, (abst).
   Google Scholar
• Smith J., Urba W., Steis R., et al. Phase II trial of interleukin-lα in combination with indomethacin in melanoma patients. Proc. Am. Soc. Clin. Oncol. 1991; 10: 293, (abst).
   Google Scholar
• Kilbourn R. G., Gross S. S., Lodato R. F., et al. Inhibition of interleukin-1-a-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-l-a-induced hypotension by Nw-amino-L-arginine. J. Natl. Cancer Inst. 1992; 84: 1008–1016
   PubMed Web of Science ®Google Scholar
• Monroy R. L., Davis T. A. Development of factor administration schedules to increase peripheral blood stem cells in normal primates: a comparison using IL-1, GM-CSF and IL-3. Blood 1991; 78(suppl. 10)163a, (abst).
   PubMedGoogle Scholar